Tuesday - June 30, 2026

Category Archives: Science

Simcoe Pest X Expands Pest Control and Wildlife Removal Services Across Bradford, Barrie, Collingwood, Innisfil, King City, Orillia, and Simcoe County

Simcoe Pest X is expanding awareness of its professional pest control and wildlife removal services across Bradford, Barrie, Collingwood, Innisfil, King City, Orillia, and nearby Simcoe County communities. The company provides residential and commercial pest control solutions for property owners … Continue reading →

EVO Water Technologies Strengthens Global Buyer Adoption of High Temperature Defoamer and Industrial Water Treatment Chemicals Amid Shift Toward Direct Manufacturer Sourcing

Shandong EVO Water Technologies Co., Ltd. EVO Water Technologies reports rising global demand for its High Temperature Defoamer and Water Treatment Chemicals as industries shift toward direct manufacturer sourcing. Serving oilfield, power, textile, and desalination sectors, the company emphasizes stable … Continue reading →

IgG4 related Disease Therapeutics Market Size is projected to grow at a CAGR of 34.60% by 2034, estimates DelveInsight

DelveInsight’s “IgG4-Related Disease Market Insights, Epidemiology, and Market Forecast- 2034” report delivers an in-depth understanding of IgG4-Related Disease, historical and forecasted epidemiology, and the IgG4-Related Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United … Continue reading →

Primary Biliary Cholangitis Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight

DelveInsight’s, “Primary Biliary Cholangitis Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Primary Biliary Cholangitis pipeline landscape. It covers the Primary Biliary Cholangitis pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Plaque Psoriasis Pipeline Shows Potential with Active Contributions from 75+ Key Companies | DelveInsight

DelveInsight’s “Plaque Psoriasis Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Plaque Psoriasis pipeline landscape. It covers the Plaque Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Pulmonary Fibrosis Pipeline Shows Potential with Active Contributions from 110+ Key Companies | DelveInsight

DelveInsight’s, “Pulmonary Fibrosis Pipeline Insight 2026” report provides comprehensive insights about 110+ companies and 140+ pipeline drugs in Pulmonary Fibrosis pipeline landscape. It covers the Pulmonary Fibrosis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Systemic Sclerosis Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

DelveInsight’s, “Systemic Sclerosis Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Systemic Sclerosis pipeline landscape. It covers the Systemic Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Tenosynovial Giant Cell Tumors Pipeline Shows Potential with Active Contributions from 5+ Key Companies | DelveInsight

DelveInsight’s, “Tenosynovial Giant Cell Tumors Pipeline Insight 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Tenosynovial Giant Cell Tumors pipeline landscape. It covers the Tenosynovial Giant Cell Tumors pipeline drug profiles, including clinical and nonclinical … Continue reading →

Zika Virus Infection Pipeline Shows Potential with Active Contributions from 12+ Key Companies | DelveInsight

DelveInsight’s “Zika Virus Infection Pipeline Insight 2026” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Zika Virus Infection pipeline landscape. It covers the Zika Virus Infection Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →